Carl Icahn appears to be a big fan of Brent Saunders. After Icahn was instrumental in placing his favorite CEO at the top of Forest Labs before it was acquired by Actavis several years ago – a deal which made then Forest Labs investor Carl Icahn hundreds of millions in profit – the billionaire investor is now doubling down on Saunders, and moments ago the billionaire investor announced that he has acquired a “large position” in Allergan, and confirms he is “very supportive of CEO Brent Saunders.”
Does this mean that Allergan, whose stock recently tumbled after the Pfizer deal was terminated due to Congressional intervention, is once again back in play?
From the release:
May 31, 2016
We have recently acquired a large position in Allergan and are very supportive of CEO Brent Saunders. We were instrumental in bringing Brent on board as the new CEO of Forest Labs a few years ago and worked cooperatively and constructively with him to help increase value for all Forest shareholders. Less than a year later Forest was acquired by Actavis (which subsequently merged with Allergan) resulting in massive gains for Forest shareholders. While we at that time disposed of our position in Forest, we still have always maintained great respect for Brent. We have every confidence in Brent’s ability to enhance value for all Allergan shareholders.
AGN stock is loving it.
via http://ift.tt/1O1FOdt Tyler Durden